Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study

Mohamed A. Kharfan‐Dabaja(Moffitt Cancer Center), Monzr M. Al Malki(City Of Hope National Medical Center), Uday Deotare(University Health Network), Renju Raj(Medical College of Wisconsin), Najla El‐Jurdi(University Hospitals of Cleveland), Navneet S. Majhail(Cleveland Clinic), Mohamad Cherry(University of Oklahoma Health Sciences Center), Qaiser Bashir(The University of Texas MD Anderson Cancer Center), Justin Darrah(City Of Hope National Medical Center), Taiga Nishihori(Moffitt Cancer Center), Hassan Sibai(University Health Network), Mehdi Hamadani(Medical College of Wisconsin), Marcos de Lima(University Hospitals of Cleveland), Aaron T. Gerds(Cleveland Clinic), George B. Selby(University of Oklahoma Health Sciences Center), Muzaffar H. Qazilbash(The University of Texas MD Anderson Cancer Center), Stephen J. Forman(City Of Hope National Medical Center), Ernesto Ayala(Moffitt Cancer Center), Jeffrey H. Lipton(University Health Network), Parameswaran Hari(Medical College of Wisconsin), Tariq Muzzafar(The University of Texas MD Anderson Cancer Center), Ling Zhang(Moffitt Cancer Center), Horatiu Olteanu(Medical College of Wisconsin), Janelle Perkins(University of South Florida), Lubomir Sokol(Moffitt Cancer Center), Ambuj Kumar(University of South Florida), Sairah Ahmed(The University of Texas MD Anderson Cancer Center)
British Journal of Haematology
October 4, 2017
10.1111/bjh.14954
Cited by 83Open Access
Full Text

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is incurable with conventional therapies. Limited retrospective data have shown durable remissions after haematopoietic cell transplantation (HCT) [allogeneic (allo) or autologous (auto)]. We conducted a multicentre retrospective study in BPDCN patients treated with allo-HCT and auto-HCT at 8 centres in the United States and Canada. Primary endpoint was overall survival (OS). The population consisted of 45 consecutive patients who received an allo-HCT (n = 37) or an auto-HCT (n = 8) regardless of age, pre-transplant therapies, or remission status at transplantation. Allo-HCT recipients were younger (50 (14-74) vs. 67 (45-72) years, P = 0·01) and had 1-year and 3-year OS of 68% [95% confidence interval (CI) = 49-81%] and 58% (95% CI = 38-75%), respectively. Allo-HCT in first complete remission (CR1) yielded superior 3-year OS (versus not in CR1) [74% (95% CI = 48-89%) vs. 0, P < 0·0001]. Allo-HCT outcomes were not impacted by regimen intensity [3-year OS for myeloablative conditioning = 61% (95% CI = 28-83%) vs. reduced-intensity conditioning = 55% (95% CI = 28-76%)]. One-year OS for auto-HCT recipients was 11% (95% CI = 8-50%). These results demonstrate efficacy of allo-HCT in BPDCN, especially in patients in CR1. Pertaining to auto-HCT, our results suggest lack of efficacy against BPDCN, but this observation is limited by the small sample size. Larger prospective studies are needed to better define the role of HCT in BPDCN.

Related Papers

No related papers found

Powered by citation graph analysis